Title
Number of items: 1.
Landay, A; Reither, K; Katsoulis, L; Beattie, T; Gardiner, N; Lenz, N; Said, K; Mfinanga, E; Pohl, C; Fielding, KLORCID logo; Jeffery, H; Kagina, BM; Hughes, EJ; Scriba, TJ; Hanekom, WA; Hoff, ST; Bang, P; Kromann, I; Daubenberger, C; Andersen, P and Churchyard, GJ (2015). Data from: Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ Lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. [Dataset]. Dryad. https://doi.org/10.5061/dryad.r61r8